 | • レポートコード：MRC2103C067 • 出版社/出版日：Mordor Intelligence / 2021年2月25日 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査資料では、世界の豚用健康管理市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別（診断検査、治療）分析、疾患別（滲出性皮膚炎、コクシジウム病、呼吸器疾患、豚赤痢、豚パルボウイルス、その他）分析、地域別分析、競争状況、市場機会/将来の見通しなどを掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の豚用健康管理市場規模：製品別（診断検査、治療） ・世界の豚用健康管理市場規模：疾患別（滲出性皮膚炎、コクシジウム病、呼吸器疾患、豚赤痢、豚パルボウイルス、その他） ・世界の豚用健康管理市場規模：地域別 ・競争状況 ・市場機会/将来の見通し |
The global swine health market is expected to register a healthy CAGR during the forecast period, owing to the increasing incidence of swine diseases. The Food and Agriculture Organization of the United Nations (FAO) 2019 report stated that a total of 62 provinces/cities reported outbreaks, about 3,700,000 pigs have died from the African swine fever (ASF). Moreover, rising investments in R&D activities in the development of novel therapeutics, a growing number of governments initiatives for the prevention of zoonotic diseases, increasing demand for livestock products are expected to propel the global swine health market.
Key Market Trends
Vaccines are Expected to Lead the Market
Vaccines are comprised of viruses, bacteria or other disease-causing organisms that have been killed or altered. Hence, they cannot cause any disease and boost up immunity. New advanced vaccines have been manufactured, which contains genetically engineered components derived from those disease agents. They are given to pigs, usually by injection, to stimulate an immune response which will protect the pigs against later natural infection with the organism from which the vaccine was derived. Most of the vaccines stimulate both a humoral response and a cell-mediated response. Vaccines can be live, containing living organisms which will multiply in the pig, or inactivated, containing only killed organisms which will not multiply in the pig. As there is a need for novel vaccines against all the disease-causing pathogens, there is a rapid increase in the R&D expenditure, which drives the vaccine segment to expand its reach to a broad spectrum of diseases. For Instance, in May 2017, Boehringer Ingelheim (BI) received approval for its FLEXMycoPRRS, the first and only combination PRRS-Mycoplasma hyopneumoniae (Mhp) vaccine was approved in the U.S. The newest addition to the existing FLEX line of combination swine vaccines helps swine producers better manage respiratory diseases as part of a customized program of whole herd health.
North America is Expected to Dominate over the Forecast Period
North America is expected to dominate the market due to the rising incidence of swine infections, such as Swine Enteric Coronavirus Diseases (SECD), porcine epidemic diarrhoea (PEDv), porcine delta coronavirus (PDCoV), which has caused significant morbidity and mortality, particularly in young piglets. The virus is endemic in swine populations in North America. In the United States, the Swine Health Protection Act (SHPA) regulates the meat products fed to swine. Compliance with this act ensures that all food waste fed to swine is properly treated to kill disease organisms. Raw meat may transmit numerous infectious or communicable diseases to swine. Over the forecast period, with the rise in the incidence of swine, the US is expected to be a major revenue-generating region for the swine health market. According to the National Center for Biotechnology Information report published in 2018, about 6 million feral swine roam in the US and are believed to be found in at least 35 states leading to the Classical swine fever (CSF) among the people in the United States
Competitive Landscape
The market players in the swine health market are involving in various growth strategies such as collaborations, partnerships, agreements, mergers, and acquisitions in order to enhance the market presence. For instance, in 2018 Elanco Animal Health, introduced Prevacent PRRS a modified-live respiratory vaccine for reduction of the porcine reproductive and respiratory syndrome (PRRS), respiratory form, in piglets two weeks or older. In May 2019, MSD Animal Health has launched its Porcilis Ery+Parvo+Lepto combination vaccine for pigs.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Swine Diseases
4.2.2 Increasing Demand for Livestock Products
4.2.3 Increasing Investments in R&D Activities to Develop Novel Therapeutics
4.3 Market Restraints
4.3.1 Stringent Regulatory Framework
4.3.2 High cost associated with Swine Health Especially in the Developing Countries
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By products
5.1.1 Diagnostic Tests
5.1.1.1 Enzyme Linked Immuno-Sorbent Assay (ELISA)
5.1.1.2 Rapid Immuno Migration (RIM)
5.1.1.3 Agar Gel Immuno-Diffusion (AGID)
5.1.1.4 Polymerase Chain Reaction (PCR)
5.1.1.5 Diagnostic Imaging
5.1.1.6 Other Diagnostics
5.1.2 Therapeutics
5.1.2.1 Vaccines
5.1.2.2 Parasiticides
5.1.2.3 Anti-infectives
5.1.2.4 Feed additives
5.1.2.5 Other Therapeutics
5.2 By Diseases
5.2.1 Exudative dermatitis (greasy pig disease)
5.2.2 Coccidiosis
5.2.3 Respiratory diseases
5.2.4 Swine dysentery
5.2.5 Porcine parvovirus
5.2.6 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 C. Boehringer Ingelheim GmBH
6.1.2 Ceva Animal Health Inc.
6.1.3 Elanco
6.1.4 IDVet
6.1.5 Merck & Co Inc.
6.1.6 Vetoquinol SA
6.1.7 Virbac
6.1.8 Zoetis Animal Healthcare
6.1.9 IDEXX Laboratories Inc.
6.1.10 Phibro Animal Health
6.1.11 Huvepharma
7 MARKET OPPORTUNITIES AND FUTURE TRENDS